ECSP21093541A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Info

Publication number
ECSP21093541A
ECSP21093541A ECSENADI202193541A ECDI202193541A ECSP21093541A EC SP21093541 A ECSP21093541 A EC SP21093541A EC SENADI202193541 A ECSENADI202193541 A EC SENADI202193541A EC DI202193541 A ECDI202193541 A EC DI202193541A EC SP21093541 A ECSP21093541 A EC SP21093541A
Authority
EC
Ecuador
Prior art keywords
braf
disorders
compounds
treatment
associated diseases
Prior art date
Application number
ECSENADI202193541A
Other languages
English (en)
Inventor
Andrew T Metcalf
Adam W Cook
David A Moreno
Brett Joseph Prigaro
Ellen Laird
Patrick Barbour
Spencer Phillip Pajk
Bradley Jon Newhouse
Katie Keaton Brown
Erik James Hicken
Eugene Tarlton
Li Ren
Dean Russell Kahn
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ECSP21093541A publication Critical patent/ECSP21093541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se adjunta resumen de la invención
ECSENADI202193541A 2019-06-28 2021-12-28 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf ECSP21093541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868581P 2019-06-28 2019-06-28
US202063021410P 2020-05-07 2020-05-07

Publications (1)

Publication Number Publication Date
ECSP21093541A true ECSP21093541A (es) 2022-01-31

Family

ID=71465389

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202193541A ECSP21093541A (es) 2019-06-28 2021-12-28 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Country Status (22)

Country Link
US (2) US11414404B2 (es)
EP (1) EP3990437A1 (es)
JP (1) JP7169469B2 (es)
KR (1) KR102712548B1 (es)
CN (1) CN114026073B (es)
AU (1) AU2020302352B2 (es)
BR (1) BR112021025102A2 (es)
CA (1) CA3144859C (es)
CO (1) CO2021017438A2 (es)
CR (1) CR20210626A (es)
CU (1) CU20210098A7 (es)
EC (1) ECSP21093541A (es)
IL (1) IL288214B2 (es)
MA (1) MA56387A (es)
MX (1) MX2021015903A (es)
PE (1) PE20220341A1 (es)
PH (1) PH12021552913A1 (es)
PY (1) PY2030114A (es)
TW (1) TWI817018B (es)
UY (1) UY38767A (es)
WO (1) WO2020261156A1 (es)
ZA (1) ZA202201329B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
SI4073065T1 (sl) * 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
CA3158541A1 (en) * 2019-12-10 2021-06-17 Cosimo Dolente New braf inhibitors as paradox breakers
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
MX2022015703A (es) * 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
CN117940130A (zh) * 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
CN117642166A (zh) * 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
JP2024522603A (ja) * 2021-06-09 2024-06-21 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト (3r)-n-[2-シアノ-4-フルオロ-3-(3-メチル-4-オキソ-キナゾリン-6-イル)オキシ-フェニル]-3-フルオロ-ピロリジン-1-スルホンアミドの新規固形物
IL308015A (en) * 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
IL312171A (en) * 2021-11-04 2024-06-01 Hoffmann La Roche Innovative use of the quinazolinone compound for cancer treatment
KR20240115893A (ko) * 2021-12-08 2024-07-26 어레이 바이오파마 인크. N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
TW202409040A (zh) * 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
JP2025537786A (ja) * 2022-11-18 2025-11-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 進行性固形がんまたは転移の治療のためのbraf阻害剤としてのキナゾリノン化合物
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025176139A1 (zh) * 2024-02-20 2025-08-28 海思科医药集团股份有限公司 一种喹唑啉酮衍生物的晶型及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20090118261A1 (en) 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
JP2009532449A (ja) 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 抗癌活性のある置換キナゾリン
WO2007113558A2 (en) 2006-04-05 2007-10-11 Astrazeneca Ab Quinazolinone derivatives having b-raf inhibitory activity
JP2009534364A (ja) * 2006-04-18 2009-09-24 アストラゼネカ アクチボラグ キナゾリン−4−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2020053019A1 (en) 2018-09-14 2020-03-19 Unilever N.V. Evaluating the efficacy of leave-on cosmetic compositions to protect skin from pollutants
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
PE20220341A1 (es) 2022-03-14
CR20210626A (es) 2022-02-08
MA56387A (fr) 2022-05-04
JP7169469B2 (ja) 2022-11-10
TWI817018B (zh) 2023-10-01
AU2020302352B2 (en) 2023-03-23
CN114026073B (zh) 2024-08-23
EP3990437A1 (en) 2022-05-04
CO2021017438A2 (es) 2022-01-17
US11414404B2 (en) 2022-08-16
PY2030114A (es) 2021-11-10
TW202114996A (zh) 2021-04-16
PH12021552913A1 (en) 2022-04-04
US20200407344A1 (en) 2020-12-31
CA3144859C (en) 2023-09-12
IL288214A (en) 2022-01-01
IL288214B1 (en) 2024-11-01
CU20210098A7 (es) 2022-06-06
UY38767A (es) 2021-01-29
WO2020261156A1 (en) 2020-12-30
AU2020302352A1 (en) 2022-01-20
JP2022539056A (ja) 2022-09-07
US20220289721A1 (en) 2022-09-15
ZA202201329B (en) 2023-09-27
KR20220011712A (ko) 2022-01-28
BR112021025102A2 (pt) 2022-01-25
IL288214B2 (en) 2025-03-01
CA3144859A1 (en) 2020-12-30
CN114026073A (zh) 2022-02-08
KR102712548B1 (ko) 2024-09-30
MX2021015903A (es) 2022-02-03
US11634409B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
EP3784260A4 (en) Compositions for the treatment of skin conditions
IL281244A (en) Combination therapy for the treatment of liver disease
EP3807270C0 (en) NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
HUE059638T2 (hu) Ízületi gyulladásos betegségek kombinált kezelése
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EP3844156A4 (en) TREATMENT OF LIVER DISEASES
EP3790563A4 (en) Compositions for the treatment of skin conditions
EP3959213C0 (en) PYRIMIDINE-BASED JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EP3583113A4 (en) USE OF TGF-ALPHA FOR THE TREATMENT OF ILLNESSES AND CONDITIONS
EP3883553A4 (en) ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER
IL282021A (en) Compounds and compositions for treating conditions associated with apj receptor activity
IL310870A (en) Quinazoline compounds for treatment of disease
EP3866795A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EP3927428C0 (en) NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
EP3877383A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES